- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03318731
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
Evaluation of the Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation on Healthy Non-resistance Trained Participants
Study Overview
Status
Conditions
Detailed Description
Subjects expressing interest in doing the study will be interviewed in the UMHB Human Performance Lab (HPL) to determine whether they qualify to participate in the study. Upon qualification, participants will be scheduled a familiarization session in which they will be taught how to perform a proper bench press, back squat, deadlift and squat thruster. They will then schedule their first testing session which will include: a body composition analysis via an InBody 770, thigh circumference measurements, joint mobility measurements, a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps). Participants will then be placed in groups based on fat free mass and assigned their workout program (3days/week) with training loads based on their 1RM values (bench press, back squat, deadlift and squat thruster).
Supplementation protocol: Participants will be randomly assigned into one of three groups and instructed to ingest capsules of either a placebo, or IND03 (fenugreek extract) containing 300mg, or 500mg. They will supplement 1 hour prior to their workout each exercise day as well as during the overreaching week. On "off/rest" days, participants will consume capsules in the morning with breakfast.
After two weeks of training, participants will return to the HPL for follow-up strength testing (1RM), and muscular endurance testing (70% 1RM max reps), then instructed to rest for 48 hours and return to the lab to begin their overreaching protocol. During each of the 5 days, participants undergo the following measurements prior to the exercise protocol: thigh circumference, joint mobility, and questionnaires (WOMAC & VAS). On Day 1 participants will also perform an InBody and blood draw. A blood draw will also be performed on Day 3. They will then consume a standardized snack and begin the overreaching protocol of 8 sets of 10 repetitions for the following 4 exercises: bench press, back squat, deadlift and squat thruster. There will be a 1 minute rest period in between each set and a 2 minute rest in between each exercise. Participants will then fill out a Rate of Perceived Exertion (RPE) immediately after the protocol. Again, they will perform this for 5 consecutive days.
Twenty-four hours after the last overreaching day, participants will return for thigh circumference, joint mobility, questionnaires (WOMAC & VAS), a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps). They will then be instructed to continue the resistance training program for 1 week. After that period they will return for final measurements of thigh circumference, joint mobility, questionnaires (WOMAC & VAS), a blood draw, strength testing (1RM), and muscular endurance testing (70% 1RM max reps).
Throughout the duration of the study, participants will record their dietary intake via MyFitnessPal.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Belton, Texas, United States, 76513
- UMHB Human Performance Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be males between the age of 18-45;
- Subjects will have not been participating in a structured resistance training program in the past 6 months;
- Subjects will be provided written and dated informed consent to participate in the study;
- Subjects will be willing and able to comply with the protocol;
- Subjects will be apparently healthy and free from disease, as determined by a health history questionnaire;
- Subjects will agree to abstain from exercise 48 hours prior to each testing visit;
- Subjects will agree to fast for 10 hours prior to each testing visit;
- Subjects will be agree to refrain from tobacco use, alcohol and/or caffeine consumption and/or smoking 12 hours prior to each testing visit;
- Subjects will agree to refrain from taking any supplement that may interfere with study supplementation for the remainder of the study.
Exclusion Criteria:
- Subject has taken ergogenic levels of nutritional supplements that may affect muscle mass (e.g., creatine, HMB) or anabolic/catabolic hormone levels (e.g., androstenedione, DHEA, etc.) within 3 months prior to the start of the study;
- Subject is unable to complete blood draws needed at each testing session;
- Subject reports any unusual adverse events associated with this study that in consultation with the supervising physician recommends removal from the study;
- Subject does not complete 90% of resistance training program assigned;
- Subject is unable to complete overreaching protocol during overreaching week;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar Pill
Maltodextrin (matches the weight of the active treatment).
Taken 1-hour prior to workout on training days and each day of overreaching week.
On rest days, will consume in the morning with breakfast.
|
Taken orally in capsule form
|
Experimental: Fenugreek Extract, Low Dose
300mg Taken 1-hour prior to workout on training days and each day of overreaching week.
On rest days, will consume in the morning with breakfast.
|
Taken orally in capsule form
|
Experimental: Fenugreek Extract, High Dose
500mg Taken 1-hour prior to workout on training days and each day of overreaching week.
On rest days, will consume in the morning with breakfast.
|
Taken orally in capsule form
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Fenugreek Extract on Interleukin-1
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on Creatine Kinase
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on Interleukin-6
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on Tumor Necrosis Factor Alpha (TNF-α)
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on C-reactive protein
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine the effectiveness of fenugreek extract on blunting an exercise-induced state of inflammation during a period of high volume and overreaching resistance exercise in young, non-resistance trained males.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on 3-methylhistidine
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Effect of Fenugreek Extract on Lactate Dehydrogenase
Time Frame: within 26 days
|
The primary purpose of this investigation is to determine if supplementation of fenugreek extract will have a protective effect on muscle damage in response to resistance exercise.
This will be accomplished by observing blood markers prior to, during and post exercise testing.
|
within 26 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Fenugreek Extract on Glucose mg/dL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Urea Nitrogen (BUN) mg/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Creatinine mg/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on eGFR Non-Afr. American mL/min/1.73m2
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on eGFR African American mL/min/1.73m2
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on BUN/Creatinine Ratio calculated
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Sodium mmol/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Potassium mmol/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Chloride mmol/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Carbon Dioxide mmol/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Calcium mg/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Protein, Total g/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Albumin g/dL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Globulin g/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Albumin/Globulin Ratio calculated
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Bilirubin, Total mg/Dl
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Alkaline Phosphatase U/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Aspartate Aminotransferase U/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Alanine Aminotransferase U/L
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a comprehensive metabolic panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on White Blood Cell Count thousand/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Red Blood Cell Count million/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Hemoglobin g/dL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Hematocrit %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on MCV fL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on MCH pg
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on MCHC g/dL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on RDW %
Time Frame: within 26 days
|
v
|
within 26 days
|
Effect of Fenugreek Extract on Platelet Count thousand/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on MPV fL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Absolute Neutrophils cells/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Absolute Lymphocytes cells/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Absolute Monocytes cells/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Absolute Eosinophils cells/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Absolute Basophils cells/uL
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Neutrophils %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Lymphocytes %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Monocytes %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Eosinophils %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Effect of Fenugreek Extract on Basophils %
Time Frame: within 26 days
|
The secondary purpose is to assess safety of ingestion of the supplement with analysis of a complete blood count panel prior to and after the supplementation period.
|
within 26 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FNG-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Oral Science International Inc.AdvarraNot yet recruiting
Clinical Trials on Sugar Pill
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
Harvard University Faculty of MedicineBeth Israel Deaconess Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompletedPeriampullary Carcinoma NosBrazil
-
GlaxoSmithKlineCompletedHealthy Subjects | Infections, BacterialAustralia
-
USDA Grand Forks Human Nutrition Research CenterCompletedInsomnia | Nutritional DeficiencyUnited States
-
Neurotune AGCross Research S.A.; Triclinium clinical trial project managment LTDCompletedNeuropathy | AIDSSouth Africa
-
Vantia LtdVeeda Clinical ResearchCompleted
-
University of California, Los AngelesCompletedAutism Spectrum DisorderUnited States
-
University of California, Los AngelesCompleted
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed